Clinic
Dignity Health
Dignity Health was paid $96.24M by Medicaid between Jan 2018 and Nov 2024, across 309 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 38% of everything it billed.
33Billing provider infoDIGNITY HEALTH
OXNARD, CA 93030
OXNARD, CA 93030
33aNPI1073665360assigned 01/17/2007
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$96.24M
24GClaims1,132,545
24DCodes billed309
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in California
Rank by total paid#1 of 347
Median peer was paid$191K
This provider vs. median504×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MORISSETTE, DANIEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 185,044 | $11.28M | |
| 2019 | 172,059 | $11.62M | |
| 2020 | 140,345 | $8.91M | |
| 2021 | 150,491 | $13.54M | |
| 2022 | 164,761 | $17.31M | |
| 2023 | 177,878 | $20.60M | |
| 2024incomplete | 141,967 | $12.98M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 38% | 78,381 | 69,705 | $36.59M |
| 0450 | Emergency room services | 11% | 83,383 | 74,113 | $10.84M |
| A4649 | Surgical supply; miscellaneous | 5.6% | 27,781 | 23,198 | $5.40M |
| 36415 | Collection of venous blood by venipuncture | 3.7% | 26,122 | 22,599 | $3.55M |
| J3490 | Unclassified drugs | 3.2% | 24,282 | 16,710 | $3.11M |
| J9271 | Injection, pembrolizumab, 1 mg | 3.1% | 433 | 325 | $2.95M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.4% | 7,944 | 7,387 | $2.29M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 2,388 | 1,392 | $1.85M |
| 80053 | Comprehensive metabolic panel | 1.6% | 64,361 | 57,681 | $1.55M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.4% | 5,512 | 5,155 | $1.31M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 7,964 | 7,721 | $1.18M |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1.2% | 1,947 | 1,224 | $1.15M |
297 more codes
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1.2% | 2,102 | $1.14M |
| J0897 | Injection, denosumab, 1 mg | 1.1% | 1,236 | $1.07M |
| 99283 | Emergency room visit (moderate) | 1.1% | 6,457 | $1.04M |
| 0360 | <1% | 3,838 | $864K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 617 | $861K |
| 0111 | <1% | 152 | $828K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 17,793 | $733K |
| 0214 | <1% | 221 | $620K | |
| 96367 | <1% | 6,323 | $589K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,630 | $549K |
| 87081 | <1% | 2,979 | $539K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 7,594 | $476K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14,302 | $476K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12,252 | $476K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,597 | $457K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,652 | $446K |
| 0272 | <1% | 1,144 | $407K | |
| 71045 | Radiologic examination, chest; single view | <1% | 29,666 | $383K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 7,708 | $339K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,090 | $337K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,744 | $332K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,605 | $331K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,338 | $323K |
| 0710 | <1% | 4,642 | $281K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,583 | $251K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,094 | $242K |
| 73610 | <1% | 2,426 | $232K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,857 | $232K |
| Z7502 | <1% | 5,868 | $221K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 6,172 | $216K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,924 | $214K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,144 | $207K |
| 73562 | <1% | 3,007 | $198K | |
| 12001 | <1% | 854 | $193K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,014 | $192K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,005 | $192K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,586 | $187K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,154 | $181K |
| 0270 | <1% | 2,753 | $176K | |
| 73130 | <1% | 2,009 | $175K | |
| 0250 | <1% | 3,183 | $163K | |
| 81001 | <1% | 26,592 | $159K | |
| 73030 | <1% | 2,209 | $155K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,843 | $147K |
| 73630 | <1% | 2,218 | $143K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,249 | $142K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 753 | $137K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,058 | $135K |
| G0378 | Hospital observation service, per hour | <1% | 566 | $126K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,356 | $125K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,372 | $122K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,843 | $122K |
| 12011 | <1% | 513 | $120K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,743 | $119K |
| 96417 | <1% | 2,569 | $118K | |
| 73110 | <1% | 1,551 | $117K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 71,709 | $115K |
| 97799 | <1% | 3,038 | $112K | |
| 99152 | <1% | 2,393 | $110K | |
| 82962 | <1% | 9,641 | $109K | |
| 86850 | <1% | 4,671 | $108K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,472 | $102K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,334 | $102K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,096 | $101K |
| 73080 | <1% | 938 | $100K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,725 | $96K |
| 87077 | <1% | 3,815 | $92K | |
| 64483 | <1% | 319 | $88K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,958 | $86K |
| 0761 | <1% | 1,578 | $86K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 33,918 | $86K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 660 | $86K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,034 | $83K |
| 73140 | <1% | 829 | $80K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,497 | $80K |
| 96415 | <1% | 1,769 | $79K | |
| 86900 | <1% | 5,261 | $78K | |
| 72100 | <1% | 1,728 | $77K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,202 | $76K |
| 81025 | <1% | 9,068 | $76K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,108 | $75K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 18 | $72K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 36 | $72K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 901 | $71K |
| 0160 | <1% | 922 | $68K | |
| 95816 | <1% | 712 | $64K | |
| 90715 | <1% | 997 | $63K | |
| 81002 | <1% | 11,026 | $61K | |
| 74018 | <1% | 1,510 | $60K | |
| 10060 | <1% | 357 | $56K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,006 | $56K |
| V2632 | Posterior chamber intraocular lens | <1% | 619 | $54K |
| 0750 | <1% | 189 | $53K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,969 | $51K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,394 | $49K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,697 | $46K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 820 | $44K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,318 | $43K |
| 97750 | <1% | 670 | $42K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,259 | $41K |
| 81000 | <1% | 3,558 | $41K | |
| 72040 | <1% | 440 | $40K | |
| 73090 | <1% | 437 | $40K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 56 | $38K |
| J1815 | Injection, insulin, per 5 units | <1% | 743 | $38K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,953 | $38K |
| 97116 | <1% | 2,233 | $38K | |
| 96368 | <1% | 1,069 | $37K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 290 | $36K |
| 73590 | <1% | 844 | $35K | |
| 71101 | <1% | 589 | $35K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 333 | $33K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 66 | $32K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 502 | $32K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 858 | $31K |
| 73502 | <1% | 818 | $30K | |
| 29125 | <1% | 422 | $29K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 903 | $29K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,981 | $27K |
| 97161 | <1% | 741 | $27K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 16 | $27K |
| 12002 | <1% | 174 | $27K | |
| 97139 | <1% | 676 | $26K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 254 | $26K |
| 87070 | <1% | 944 | $25K | |
| Z9725 | <1% | 838 | $25K | |
| 83880 | <1% | 12,903 | $24K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,686 | $24K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,566 | $24K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 28 | $23K |
| 93970 | <1% | 664 | $23K | |
| 84484 | <1% | 20,502 | $21K | |
| 95819 | <1% | 325 | $21K | |
| 84702 | <1% | 6,745 | $21K | |
| 0636 | <1% | 343 | $21K | |
| 93971 | <1% | 1,555 | $21K | |
| 11043 | <1% | 174 | $21K | |
| 70486 | <1% | 929 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,561 | $20K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,264 | $20K |
| 85610 | <1% | 10,328 | $19K | |
| 97014 | <1% | 712 | $19K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 957 | $18K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,457 | $17K |
| 96523 | <1% | 251 | $17K | |
| 80047 | <1% | 524 | $16K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,046 | $16K |
| 80076 | <1% | 2,401 | $16K | |
| 0760 | <1% | 233 | $15K | |
| 83690 | <1% | 28,388 | $14K | |
| 76801 | <1% | 2,549 | $13K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 63 | $13K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 60 | $13K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 175 | $13K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 634 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,667 | $12K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,341 | $12K |
| 88304 | <1% | 778 | $12K | |
| 84703 | <1% | 7,768 | $11K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 58 | $11K |
| 81003 | <1% | 16,930 | $11K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $10K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,581 | $10K |
| 85730 | <1% | 7,837 | $10K | |
| 70496 | <1% | 471 | $10K | |
| C1769 | Guide wire | <1% | 573 | $9K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 123 | $9K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 548 | $9K |
| 87040 | <1% | 5,899 | $9K | |
| 85027 | <1% | 4,101 | $8K | |
| 87634 | <1% | 1,892 | $7K | |
| 70498 | <1% | 360 | $7K | |
| 86901 | <1% | 5,260 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,687 | $7K |
| 0720 | <1% | 130 | $7K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 145 | $7K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,097 | $7K |
| 83735 | <1% | 6,155 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 212 | $6K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 39 | $6K |
| 97039 | <1% | 334 | $6K | |
| 83605 | <1% | 7,935 | $6K | |
| 84145 | <1% | 2,850 | $6K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 39 | $6K |
| 93976 | <1% | 384 | $5K | |
| 96411 | <1% | 163 | $5K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 60 | $4K |
| 76870 | <1% | 175 | $4K | |
| 86308 | <1% | 166 | $4K | |
| 94664 | <1% | 655 | $4K | |
| 0258 | <1% | 114 | $4K | |
| 87807 | <1% | 422 | $4K | |
| 36902 | <1% | 12 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,366 | $4K |
| 0278 | <1% | 12 | $3K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 27 | $3K |
| A9270 | Non-covered item or service | <1% | 5,090 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 80 | $3K |
| 71250 | <1% | 51 | $3K | |
| 85379 | <1% | 4,301 | $3K | |
| 82803 | <1% | 488 | $3K | |
| 93798 | <1% | 128 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 38 | $3K |
| 82550 | <1% | 4,369 | $3K | |
| 87186 | <1% | 3,043 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 25 | $3K |
| 85007 | <1% | 2,653 | $2K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 93 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 361 | $2K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,598 | $2K |
| 64493 | <1% | 18 | $2K | |
| 86701 | <1% | 41 | $2K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 131 | $2K |
| 86140 | <1% | 2,781 | $2K | |
| 80061 | Lipid panel | <1% | 1,270 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 34 | $2K |
| 87506 | <1% | 60 | $2K | |
| 96402 | <1% | 99 | $2K | |
| 88307 | <1% | 12 | $2K | |
| 72131 | <1% | 39 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 386 | $2K |
| 59025 | Fetal non-stress test | <1% | 57 | $2K |
| 96376 | <1% | 1,045 | $1K | |
| 87205 | <1% | 986 | $1K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 127 | $1K |
| 84100 | <1% | 1,553 | $1K | |
| 93017 | <1% | 24 | $1K | |
| 86703 | <1% | 1,226 | $1K | |
| 82140 | <1% | 333 | $1K | |
| 94760 | <1% | 1,512 | $1K | |
| 86780 | <1% | 140 | $1K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 18 | $880.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 272 | $879.22 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 207 | $850.17 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 493 | $848.04 |
| 0301 | <1% | 344 | $835.45 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 41 | $815.15 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 16 | $812.36 |
| 83615 | <1% | 334 | $626.15 | |
| 84550 | <1% | 47 | $526.84 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 34 | $511.67 |
| 88312 | <1% | 34 | $478.86 | |
| 0352 | <1% | 105 | $474.23 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 49 | $469.00 |
| 36600 | <1% | 91 | $446.93 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 72 | $443.01 |
| 29505 | <1% | 13 | $430.00 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 18 | $411.65 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 27 | $372.00 |
| 85014 | <1% | 875 | $314.53 | |
| 96150 | <1% | 14 | $259.28 | |
| 0306 | <1% | 240 | $254.36 | |
| C9399 | Unclassified drugs or biologicals | <1% | 87 | $231.84 |
| 85651 | <1% | 821 | $216.75 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 71 | $214.75 |
| 76770 | <1% | 12 | $195.62 | |
| 72110 | <1% | 12 | $170.08 | |
| 86769 | <1% | 44 | $168.52 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 55 | $142.76 |
| 82010 | <1% | 375 | $142.68 | |
| 71020 | <1% | 16 | $142.26 | |
| 87147 | <1% | 128 | $136.18 | |
| 82553 | <1% | 264 | $117.94 | |
| 82570 | <1% | 13 | $115.31 | |
| 90686 | <1% | 21 | $114.87 | |
| 0730 | <1% | 235 | $94.08 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 19 | $85.75 |
| 0324 | <1% | 243 | $81.93 | |
| 0305 | <1% | 329 | $63.12 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 49 | $51.22 |
| 84439 | <1% | 30 | $30.52 | |
| 0302 | <1% | 36 | $24.98 | |
| 0320 | <1% | 13 | $21.79 | |
| 0307 | <1% | 213 | $14.52 | |
| 82728 | <1% | 73 | $13.63 | |
| 84132 | <1% | 14 | $9.02 | |
| 0300 | <1% | 316 | $4.80 | |
| 85347 | <1% | 26 | $4.79 | |
| 91301 | <1% | 12 | $0.12 | |
| 0460 | 0% | 28 | $0.00 | |
| 0412 | 0% | 58 | $0.00 | |
| 73000 | 0% | 12 | $0.00 | |
| 0424 | 0% | 154 | $0.00 | |
| 29105 | 0% | 12 | $0.00 | |
| 0489 | 0% | 16 | $0.00 | |
| 0351 | 0% | 39 | $0.00 | |
| 0430 | 0% | 14 | $0.00 | |
| 0260 | 0% | 41 | $0.00 | |
| 0402 | 0% | 23 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 16 | $0.00 |
| 29515 | 0% | 13 | $0.00 | |
| 0370 | 0% | 301 | $0.00 | |
| 0434 | 0% | 33 | $0.00 | |
| 0420 | 0% | 111 | $0.00 | |
| 0410 | 0% | 16 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| 73660 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISSETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationDIGNITY HEALTH
| Provider | Location | Paid |
|---|---|---|
| Dignity Health | San Bernardino, CA | $133.09M |
| Dignity Health | Phoenix, AZ | $126.19M |
| Dignity Health | Bakersfield, CA | $109.22M |
| Dignity Health | Merced, CA | $106.54M |
| Dignity Health | Carmichael, CA | $97.28M |
| Dignity Health | Redding, CA | $92.21M |
| Dignity Health | Long Beach, CA | $59.98M |
| Dignity Health | Sacramento, CA | $45.52M |
| Dignity Health | Folsom, CA | $45.14M |
| Dignity Health | Red Bluff, CA | $39.92M |
| Dignity Health | Santa Cruz, CA | $33.59M |
| Dignity Health | Gilbert, AZ | $28.49M |
| Dignity Health | Glendale, AZ | $26.30M |
| Dignity Health | Henderson, NV | $18.73M |
| Dignity Health | Mount Shasta, CA | $15.62M |
| Dignity Health | Henderson, NV | $8.52M |
| Dignity Health | Las Vegas, NV | $7.93M |
| Dignity Health | Camarillo, CA | $6.31M |
| Dignity Health | Santa Maria, CA | $5.79M |
| Dignity Health | Corning, CA | $3.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.